Last reviewed · How we verify
Early Dual IV Antibiotic Therapy - MSSA
Early dual IV antibiotic therapy uses two intravenous antibiotics simultaneously to treat methicillin-sensitive Staphylococcus aureus (MSSA) infections with broader coverage and reduced resistance risk.
Early dual IV antibiotic therapy uses two intravenous antibiotics simultaneously to treat methicillin-sensitive Staphylococcus aureus (MSSA) infections with broader coverage and reduced resistance risk. Used for Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia and serious infections, MSSA endocarditis, MSSA pneumonia.
At a glance
| Generic name | Early Dual IV Antibiotic Therapy - MSSA |
|---|---|
| Also known as | cefazolin, ertapenem, rifampin |
| Sponsor | West Virginia University |
| Drug class | Antibiotic combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a clinical treatment protocol rather than a single drug entity. It combines two IV antibiotics (typically a beta-lactam such as nafcillin or oxacillin with an aminoglycoside or fluoroquinolone) to provide synergistic bactericidal activity against MSSA. The dual approach aims to improve clinical outcomes, reduce mortality, and minimize the emergence of antibiotic resistance compared to monotherapy.
Approved indications
- Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia and serious infections
- MSSA endocarditis
- MSSA pneumonia
Common side effects
- Nephrotoxicity (aminoglycoside-related)
- Ototoxicity (aminoglycoside-related)
- Hypersensitivity reactions (beta-lactam-related)
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: